As a result of this transaction, Ablynx now has 43,709,895 shares outstanding.
About AblynxAblynxis a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipelineand seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact: Ablynx:Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
M:Communications:Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t: +44 207 920 2330
Certain statements, beliefs and opinions in this press
release are forward-looking, which reflect the Company's or,
as appropriate, the Company's directors' current expectations
and projections about future events. By their nature, forward
- looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events,
performance or results to differ significantly from any
anticipated development. Forward looking statements contained
in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, the
Company expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking
statements in this press release as a result of any change in
expectations or any change in events, conditions, assumptions
or circumstances on which these forward-looking statements
are based. Neither the
Company nor its advisers or representatives nor any of its or
their parent or subsidiary undertakings or any such person's
officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from
errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained
in this press release or the actual occurrence of the
forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the
date of this press release.
distributed by |